weight loss plateau strategies glp-1 medications maintenance after discontinuation of therapies GLP-1 Plateaus: Why They Happen

Discussions of microdosing often emerge when patients experience difficulty tolerating those starting doses or when clinicians attempt slower dose escalation

Howard Krauss, MD, a surgical neuro-ophthalmologist and director of Pacific Neuroscience Institutes Eye, Ear & Skull Base Center in Santa Monica, California, stresses that Mass Eye and Ear (which was behind the initial research connecting NAION to semaglutide) is a specialty clinic

21 Tennessee Medicaid approved coverage effective January 1, 2026

Because GLP-2 acts through subepithelial myofibroblasts, which are the same cell population implicated in intestinal fibrogenesis, the risk-benefit profile of GLP-2 agonism may differ substantially between mucosal UC, inflammatory ileal CD, and stricturing or penetrating CD phenotypes, and this phenotypic stratification should be a required feature of future trial design

Discontinuation was defined as a gap of 60 days from the last GLP-1based treatment supply day, allowing for GLP-1 drug-type switching (eg, semaglutide to tirzepatide)